Skip to main content

Master of Public Health

Antibody response to symptomatic infection with SARS-CoV-2 Omicron variant viruses, December 2021-June 2022

AUTHORS

Sandford R , Yadav R , Noble EK , Sumner K , Joshi D , Tartof SY , Wernli KJ , Martin ET , Gaglani M , Zimmerman RK , Talbot HK , Grijalva CG , Belongia EA , Carlson C , Coughlin M , Flannery B , Pearce B , Rogier E , . medRxiv : the preprint server for health sciences. 2023 11 18; ().

ABSTRACT

To describe humoral immune responses to symptomatic SARS-CoV-2 infection, we assessed immunoglobulin G binding antibody levels using a commercial multiplex bead assay against SARS-CoV-2 ancestral spike protein receptor binding domain (RBD) and nucleocapsid protein (N). We measured binding antibody units per mL (BAU/mL) during acute illness within 5 days of illness onset and during convalescence in 105 ambulatory patients with laboratory-confirmed SARS-CoV-2 infection with Omicron variant viruses. Comparing acute- to convalescent phase antibody concentrations, geometric mean anti-N antibody concentrations increased 47-fold from 5.5 to 259 BAU/mL. Anti-RBD antibody concentrations increased 2.5-fold from 1258 to 3189 BAU/mL.

Tags: